GenSight Biologics publie sa situation nette de trésorerie à la fin de l’année 2024 et fait le point sur ses activités
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 23 2025
0mins
Should l Buy ?
Source: Businesswire
Financial Situation: GenSight Biologics reported a cash position of €2.5 million as of December 31, 2024, down from €3.4 million in September 2024, and is seeking to optimize cash management while awaiting regulatory approval for its compassionate access program.
Regulatory Developments: The French National Agency for the Safety of Medicines (ANSM) is reviewing GenSight's quality dossier for LUMEVOQ, with preparations underway for a new Phase III clinical trial and submission to the UK regulatory agency MHRA.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
